---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026398"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:52:10.621467+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M

## Summary
- Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.
- Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.
- Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.
- Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.
- Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch.

## SEC filing metadata
- accession: 0001104659-26-026398
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465926026398/0001104659-26-026398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465926026398/elut-20260303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026398
- JSON: https://secwatch.observer/filing/0001104659-26-026398.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.